Drugs / HBM1020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05824663 | May 2023 → Oct 2024 | neoplasm | Harbour BioMed US, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-09-14 | Harbour BioMed (Guangzhou) Co. Ltd. | Results Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 harbourbiomed.com ↗
All 17 patients completed the dose-limiting toxicity (DLT) observation period (21 days), and no DLT events were observed. |
| 2023-01-12 | Harbour BioMed (Guangzhou) Co. Ltd. | Regulatory Harbour BioMed Announces IND Clearance for First-in-Class Anti-B7H7 (HHLA2) Antibody by the U.S. FDA harbourbiomed.com ↗
announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to commence clinical trials of its globally first-in-class fully human monoclonal antibody HBM1020 targeting B7H7 (also known as HHLA2) in the U.S. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-14 | Harbour BioMed (Guangzhou) Co. Ltd. | Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 harbourbiomed.com ↗ |
| 2024-07-26 | Harbour BioMed (Guangzhou) Co. Ltd. | Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024 harbourbiomed.com ↗ |
| 2023-06-05 | Harbour BioMed (Guangzhou) Co. Ltd. | Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020 harbourbiomed.com ↗ |
| 2023-01-12 | Harbour BioMed (Guangzhou) Co. Ltd. | Harbour BioMed Announces IND Clearance for First-in-Class Anti-B7H7 (HHLA2) Antibody by the U.S. FDA harbourbiomed.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBM1020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05824663 ↗ |
| Modality | Monoclonal antibody | “recombinant fully human anti-B7H7 monoclonal antibody” NCT05824663 ↗ |
| Route | Intravenous | “Intravenous (IV) Administrations on Days 1 of each 21-day treatment cycle.” NCT05824663 ↗ |